Skip to content
Inciteful Med

Treating and Managing AGS

Last updated:

Aicardi-Goutières syndrome (AGS) is managed using JAK inhibitors to reduce severe inflammation and symptomatic therapies for neurological issues. While these medications cannot reverse existing brain damage, continuous treatment is vital to control fevers, clear skin sores, and prevent disease flares.

Key Takeaways

  • • JAK inhibitors help control the severe inflammation of AGS but cannot reverse prior brain damage.
  • • Continuous medication is required to prevent rapid rebound flares of disease symptoms.
  • • Children on JAK inhibitors have suppressed immune systems and require emergency medical care for any fevers.
  • • Neurological symptoms like seizures, stiffness, and feeding difficulties require dedicated symptomatic management.
  • • Regular check-ups are necessary to monitor thyroid, liver, and kidney health during treatment.

Managing Aicardi-Goutières syndrome (AGS) requires a two-part approach: targeted therapy to dampen the underlying immune “fire” and symptomatic management to help your child feel comfortable and supported in their daily life [1][2].

Targeted Therapy: JAK Inhibitors

The most significant advancement in AGS treatment is the use of medications called JAK inhibitors (such as baricitinib, tofacitinib, or ruxolitinib) [3][4].

  • How They Work: Think of these drugs as “volume knobs” for the immune system. In AGS, the body’s “viral alarm” (the interferon pathway) is turned up to the maximum setting [1]. JAK inhibitors work by blocking the signals that allow this alarm to keep ringing, effectively turning down the volume on the inflammation [4][5].
  • Stopping the Fire vs. Rebuilding the House: It is helpful to use a house-fire analogy. JAK inhibitors are excellent at “putting out the fire” (stopping active inflammation) [6]. They can significantly improve systemic symptoms like unexplained fevers, skin sores (chilblains), and some autoimmune features [6][7]. However, they cannot “rebuild the house”—meaning they generally cannot reverse brain damage or structural changes that occurred before the treatment began [3][8].
  • Continuous Therapy is Vital: Because AGS is a genetic condition, the body will continue to try and “turn the volume back up” if the medication is stopped [9]. Interrupting treatment, even for a short time, can lead to a rebound flare, where symptoms like irritability, fevers, or rashes return quickly [9][10].

Crucial Safety Warning: Immunosuppression Risks

While JAK inhibitors are life-changing for many children, they suppress the immune system [11]. This means the medication that stops the body from attacking itself also makes the body less able to fight off real, everyday infections [12].

  • Infection Risk: Your child will be more vulnerable to viruses, bacterial infections, and fungal infections [11].
  • The Fever Dilemma: Children with AGS often get “sterile fevers” (fevers caused by the disease, not a bug) [13]. However, when on JAK inhibitors, you must treat every fever as a potential serious infection. Work with your doctor to establish an emergency protocol for when to seek immediate medical attention (e.g., ER visit) for a fever or signs of illness.
  • Vaccines: Children on immune-modulating drugs like JAK inhibitors generally must avoid live vaccines (such as MMR or Varicella), as the weakened immune system cannot handle them safely [14]. Always consult your immunologist or care team before your child receives any vaccine.

Managing Neurological Symptoms

While JAK inhibitors target the immune system, other treatments focus on managing the symptoms caused by the initial phase of the disease [2].

  • Seizures: If your child experiences seizures, they will likely be prescribed anti-epileptic drugs (AEDs) like levetiracetam [15][16].
  • Stiffness (Spasticity and Dystonia): Muscles that are tight or difficult to move are common in AGS [17]. These are managed through a combination of physical therapy and medications (like muscle relaxants) that help the brain and muscles communicate more smoothly [16][18].
  • Feeding: Children with swallowing difficulties may need feeding therapy, special diets, or gastrostomy tubes (G-tubes) to prevent aspiration and ensure proper nutrition [19].
  • Monitoring Organ Health: Regardless of treatment, children with AGS need regular check-ups to monitor their thyroid function, liver enzymes, and kidney health, as the underlying condition can sometimes affect these organs over time [20][21][22].

What to Expect from Treatment

Research shows that while JAK inhibitors are most effective at clearing skin rashes and reducing the “interferon score” in the blood, their impact on motor skills is more varied [23][24]. Some families notice their child becomes more alert, interacts more, or learns new ways to communicate, even if physical stiffness remains [23][16]. The goal of treatment is to lower the overall inflammatory burden on the body and provide the best possible quality of life [19][24].

Frequently Asked Questions

How do JAK inhibitors treat Aicardi-Goutières syndrome?
JAK inhibitors work by blocking the signals that cause severe inflammation in AGS. They act like a volume knob to turn down the body's overactive immune response, which helps clear skin sores, reduce fevers, and improve overall comfort.
Can JAK inhibitors reverse brain damage caused by AGS?
No, JAK inhibitors cannot reverse brain damage or structural changes that have already occurred. They are highly effective at stopping active inflammation from causing more harm, but they cannot repair past injury to the brain.
What happens if my child stops taking their AGS medication?
Interrupting treatment can lead to a rapid rebound flare of the disease. Because AGS is a genetic condition, the immune system will quickly resume its inflammatory response if medication is stopped, causing symptoms like irritability and fevers to return.
Why is fever management different for a child on JAK inhibitors?
Children with AGS often have 'sterile fevers' caused by the disease itself. However, because JAK inhibitors suppress the immune system, any fever must be treated as a potential life-threatening infection requiring immediate medical evaluation.
How are the neurological symptoms of AGS managed?
Neurological symptoms are managed with specific therapies tailored to the child. This may include anti-epileptic drugs for seizures, muscle relaxants and physical therapy for stiffness, and feeding tubes if swallowing becomes difficult.

Questions for Your Doctor

  • • Which specific JAK inhibitor (baricitinib, tofacitinib, or ruxolitinib) is most appropriate for our child's genetic subtype?
  • • What are the specific warning signs of infection we should look for while our child is on immunosuppression, and when should we go straight to the ER?
  • • How often will we need to test our child's 'interferon score' to ensure the medication dose is correct?
  • • Are there any scheduled vaccines our child should skip or delay because of the immune-suppressing medications?
  • • Can you help us coordinate with a physical therapist and GI specialist to manage stiffness and feeding issues that JAK inhibitors might not address?

Questions for You

  • • Are you able to maintain a strict daily schedule for your child's medications to prevent disease flares?
  • • Have you noticed any improvements in your child's comfort, skin health, or alertness since starting treatment?
  • • What are your primary goals for treatment—is it reducing fevers, improving skin sores, or helping with communication?
  • • Do you have an emergency plan in place for distinguishing a standard AGS fever from an active infection fever?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Aicardi-Goutières syndrome: A monogenic type I interferonopathy.

    Liu A, Ying S

    Scandinavian journal of immunology 2023; (98(4)):e13314 doi:10.1111/sji.13314.

    PMID: 37515439
  2. 2

    New Phenotypes Associated With Pathogenic RNASEH2B and SAMHD1 Variants.

    Abdel-Salam GMH, Eid M, El-Serafy MA, et al.

    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 2025; (85(3)):e70019 doi:10.1002/jdn.70019.

    PMID: 40302656
  3. 3

    Neuropathologic Impacts of JAK Inhibitor Treatment in Aicardi-Goutières Syndrome.

    Jafarpour S, Suddock J, Hawes D, Santoro JD

    Journal of clinical immunology 2024; (44(3)):68 doi:10.1007/s10875-024-01672-2.

    PMID: 38381212
  4. 4

    Ruxolitinib in Aicardi-Goutières syndrome.

    Mura E, Masnada S, Antonello C, et al.

    Metabolic brain disease 2021; (36(5)):859-863 doi:10.1007/s11011-021-00716-5.

    PMID: 33721182
  5. 5

    Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi-Goutières syndrome.

    Han VX, Mohammad SS, Jones HF, et al.

    Developmental medicine and child neurology 2022; (64(2)):266-271 doi:10.1111/dmcn.15025.

    PMID: 34415581
  6. 6

    Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.

    Li W, Wang W, Wang W, et al.

    Frontiers in immunology 2022; (13()):825367 doi:10.3389/fimmu.2022.825367.

    PMID: 35418997
  7. 7

    Overlapping Aicardi-Goutières and Singleton-Merten syndromes with a heterozygous gain-of-function mutation in IFIH1 mimicking juvenile idiopathic arthritis.

    Yamazaki S, Kaneko S, Shimbo A, et al.

    Immunological medicine 2025; (48(3)):256-260 doi:10.1080/25785826.2025.2479148.

    PMID: 40116369
  8. 8

    Case report: Pneumocystis jirovecii pneumonia in a severe case of Aicardi-Goutières syndrome with an IFIH1 gain-of-function mutation mimicking combined immunodeficiency.

    Železnik M, Soltirovska Šalamon A, Debeljak M, et al.

    Frontiers in immunology 2022; (13()):1033513 doi:10.3389/fimmu.2022.1033513.

    PMID: 36685504
  9. 9

    One mutation, divergent journeys: expanding the clinical spectrum of homozygous SAMHD1 deficiency in childhood.

    Emreol HE, Ünal D, Ayvaz DNC, et al.

    Rheumatology (Oxford, England) 2026; (65(1)) doi:10.1093/rheumatology/keaf695.

    PMID: 41496005
  10. 10

    Tofacitinib treatment for psoriatic skin lesions associated with Aicardi-Goutières syndrome 7/Singleton-Merten syndrome 1.

    Beerepoot S, Grinwis L, Vanderver AL, et al.

    Orphanet journal of rare diseases 2025; (20(1)):155 doi:10.1186/s13023-025-03675-7.

    PMID: 40176112
  11. 11

    Exploring emerging JAK inhibitors in the treatment of Aicardi-Goutières syndrome.

    Politano D, Tonduti D, Battini R, et al.

    Expert opinion on emerging drugs 2024; 1-19 doi:10.1080/14728214.2024.2445508.

    PMID: 39704072
  12. 12

    JAK: Not Just Another Kinase.

    Agashe RP, Lippman SM, Kurzrock R

    Molecular cancer therapeutics 2022; (21(12)):1757-1764 doi:10.1158/1535-7163.MCT-22-0323.

    PMID: 36252553
  13. 13

    Systemic complications of Aicardi Goutières syndrome using real-world data.

    Peixoto de Barcelos I, Jan AK, Modesti N, et al.

    Molecular genetics and metabolism 2024; (143(1-2)):108578 doi:10.1016/j.ymgme.2024.108578.

    PMID: 39332260
  14. 14

    A novel patient-Centered approach to clinical trial readiness in rare diseases: Application in Aicardi-Goutières Syndrome (AGS).

    Sevagamoorthy A, Gavazzi F, Tashnim Z, et al.

    Molecular genetics and metabolism 2026; (147(3)):109765 doi:10.1016/j.ymgme.2026.109765.

    PMID: 41671914
  15. 15

    The Rare Syndrome Aicardi-Goutières 4: A Case Report and Literature Review.

    Aydin H, Bolat H

    Developmental neurobiology 2025; (85(2)):e22965 doi:10.1002/dneu.22965.

    PMID: 40263931
  16. 16

    TREX-1 related Aicardi-Goutières syndrome improved by Janus kinase inhibitor.

    Ryckmans C, Donge M, Marchèse A, et al.

    American journal of medical genetics. Part A 2024; (194(5)):e63510 doi:10.1002/ajmg.a.63510.

    PMID: 38135344
  17. 17

    Diagnosis of Aicardi-Goutières Syndrome in Adults: A Case Series.

    Videira G, Malaquias MJ, Laranjinha I, et al.

    Movement disorders clinical practice 2020; (7(3)):303-307 doi:10.1002/mdc3.12903.

    PMID: 32258229
  18. 18

    Baricitinib Treatment in RNU7-1-Associated Aicardi-Goutières Syndrome in a South African Child: A Case Report.

    Spracklen TF, Akhalwaya S, Ackermann S, et al.

    American journal of medical genetics. Part A 2025; (197(5)):e63978 doi:10.1002/ajmg.a.63978.

    PMID: 39748568
  19. 19

    Experiences and Hope in Caregivers of Children With Aicardi Goutières Syndrome.

    Gavazzi F, Martin A, Sevagamoorthy A, et al.

    Journal of child neurology 2025; (40(7)):543-554 doi:10.1177/08830738251341530.

    PMID: 40400365
  20. 20

    Endocrinopathies in Aicardi Goutières syndrome-A descriptive case series.

    Worth C, Briggs TA, Padidela R, et al.

    Clinical case reports 2020; (8(11)):2181-2185 doi:10.1002/ccr3.3081.

    PMID: 33235754
  21. 21

    Hepatic Involvement in Aicardi-Goutières Syndrome.

    Gavazzi F, Cross ZM, Woidill S, et al.

    Neuropediatrics 2021; (52(6)):441-447 doi:10.1055/s-0040-1722673.

    PMID: 33445189
  22. 22

    Collapsing Glomerulopathy as a Complication of Type I Interferon-Mediated Glomerulopathy in a Patient With RNASEH2B-Related Aicardi-Goutières Syndrome.

    Fenaroli P, Rossi GM, Angelotti ML, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (78(5)):750-754 doi:10.1053/j.ajkd.2021.02.330.

    PMID: 33872687
  23. 23

    Treatment response to Janus kinase inhibitor in a child affected by Aicardi-Goutières syndrome.

    Galli J, Cattalini M, Loi E, et al.

    Clinical case reports 2023; (11(8)):e7724 doi:10.1002/ccr3.7724.

    PMID: 37534202
  24. 24

    JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study.

    Frémond ML, Hully M, Fournier B, et al.

    Journal of clinical immunology 2023; (43(6)):1436-1447 doi:10.1007/s10875-023-01500-z.

    PMID: 37171742

This page provides educational information on managing Aicardi-Goutières syndrome. Always consult your pediatric neurologist or immunologist regarding your child's specific treatment plan.

Stay up to date

Get notified when new research about Aicardi-Goutières syndrome is published.

No spam. Unsubscribe anytime.